Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.

@article{Muscedere2010MortalityAM,
  title={Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.},
  author={John Muscedere and Andrew George Day and Daren Keith Heyland},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2010},
  volume={51 Suppl 1},
  pages={S120-5}
}
Appropriate end points are crucial for the successful interpretation of clinical trials. Choosing end points for therapeutic trials of ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) requires careful consideration, because they are complications of critical illness. It may be difficult to distinguish the consequences of VAP and HAP from manifestations of the underlying illnesses, and it is important to determine their incremental magnitude, to plan for possible… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection

  • J Beyersmann, P Gastmeier
  • Infect Control Hosp Epidemiol
  • 2006
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…